Nav: Home

Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment

October 11, 2019

The authors have developed the Accelera TED platform to repurpose drugs for HNSCC treatment; using in vitro assays and in vivo models.

Screening a library of clinically-approved drugs identified the anti-malarial agent quinacrine as a candidate, which significantly reduced viability in a concentration dependent manner in five HNSCC cell lines and in six primary HNSCC samples.

In vivo, daily treatment with 100 mg/kg oral quinacrine plus cisplatin significantly inhibited tumor outgrowth, extending median time to reach maximum tumor volume from 20 to 32 days versus control, and from 28 to 32 days versus 2 mg/kg cisplatin alone.

Dr. Hisham Mehanna and Dr. Nikolaos Batis said, "Head and neck squamous cell carcinoma is a debilitating disease comprising 600,000 cases per year worldwide"

Due to the high morbidity of current treatments, quality of life is severely impaired, with evident unmet need necessitating more effective therapies with lower toxicity; especially as recent studies examining cetuximab as a less toxic alternative for low risk human papillomavirus positive HNSCC have shown similar toxicity, and lower efficacy compared to cisplatin.

On initial screening against HNSCC cell lines, quinacrine was identified as a potential hit.

Quinacrine is a potent late-stage autophagy inhibitor and has been shown to prime cells to the effects of cisplatin via apoptosis in cervical and endometrial cancer.

Further mechanistic insights have been demonstrated in HNSCC whereby quinacrine was able to restore the function of the tumor suppressive protein, tumor protein 53, leading to enhanced capabilities of initiating apoptotic cell death following DNA damage with cisplatin chemotherapy; Moreover, quinacrine treatment has been shown to suppress phosphoinositide 3-kinase, protein kinase B, mechanistic target of rapamycin and nuclear factor kappa-light-chain-enhancer of activated B cells pathways.

The Mehanna/Batis Research team concluded, "Notably, our study is the first to demonstrate that quinacrine is able to reduce tumor burden in mice bearing HNSCC xenograft tumors, using concentrations that are clinically relevant."
-end-
Full text - http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=27156&path%5B%5D=86845

Correspondence to - Hisham Mehanna - h.mehanna@bham.ac.uk and Nikolaos Batis - n.batis@bham.ac.uk

Keywords - head and neck cancer, drug repurposing, drug repositioning, quinacrine, mepacrine

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

Oncotarget is published by Impact Journals LLC.

To learn more about Oncotarget, please visit http://www.ImpactJournals.com

Impact Journals LLC

Related Cisplatin Articles:

One drug, three action modes
Clinicians combat the drug resistances of some cancer types by using a combination of different drugs.
Oncotarget: Both BRCA1-wild type and -mutant triple-negative breast cancers show
Oncotarget Volume 11 Issue 8 features Figure 8, 'MLN4924 treatment induces DNA damage by stabilizing CDT1 and accumulates the cells in S phase which are enhanced by MLN4924/cisplatin co-treatment,' by Misra, et al.
NUS researchers identify novel protein to prevent neuropathy from chemotherapy
A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy, a major side effect of chemotherapy, in cancer patients.
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
Oncotarget Volume 11, Issue 4: In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin - radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}.
Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment
The authors have developed the Accelera TED platform to repurpose drugs for HNSCC treatment; using in vitro assays and in vivo models.
Response rate to albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b/2 pilot clinical trial
Published today in the Journal of the American Medical Association (JAMA) Oncology, researchers at HonorHealth Research Institute and TGen, an affiliate of City of Hope, found that among a clinical trial of 25 patients, adding the drug cisplatin to a current standard-of-care drug regimen resulted in substantial tumor shrinkage for 71 percent of those patients, and dramatically increased survival beyond one year.
Reduced-dose IMRT w/ cisplatin meets predetermined benchmarks for PFS and swallowing-related QOL
Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer.
Researchers clock DNA's recovery time after chemotherapy
A team of researchers led by Nobel laureate Aziz Sancar found that DNA damaged by the widely used chemotherapy drug cisplatin is mostly good as new in noncancerous tissue within two circadian cycles, or two days.
Drug makes tumors more susceptible to chemo
Researchers at MIT and Duke University have discovered a potential drug compound that can block a mutagenic DNA repair pathway that helps cancer cells survive chemotherapy.
Chemotherapeutic drugs and plasma proteins: Exploring new dimensions
This review provides a bird's eye view of interaction of a number of clinically important drugs currently in use that show covalent or non-covalent interaction with serum proteins.
More Cisplatin News and Cisplatin Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.